GoAI
Get started
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc.

SRPT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$18.79

−$0.43 · -2.24%

Aug 21, 4:00 PM ET

SRPT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

80

Undervalued

Momentum

45

Neutral

Sentiment

71

Bullish

Risk resilience

55

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Michael E. Severino
Listed since
Jun 4, 1997
Employees
835

Market position

Day range

Current $18.79

52-week range

Current $18.79

Open
$19.39
Previous close
$19.22
Volume
1.67M
0.52× average
Average volume
3.2M
Average daily volume
Market cap
1.98B USD
Beta
0.21
Market reference 1
50-day average
$17.2898
+8.68% above average
200-day average
$19.0178
-1.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.49B USD
P/E (TTM)
-13.05×
P/B (TTM)
1.3×
P/S (TTM)
1×
EV / EBITDA
-3.85×
Earnings yield
-31.63%
Free cash flow yield
-13.63%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
58.56%
Operating margin
-7.26%
Net margin
-6.93%
Return on equity
-62.55%
Return on assets
-21.30%
Return on invested capital
-29.03%

Financial health

Debt / equity
0.68×
Current ratio
2.32×
Altman Z-score
-0.08
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends104%39%-26%-92%Gross margin, FY2021: 86.17%Gross margin, FY2022: 85.00%Gross margin, FY2023: 87.91%Gross margin, FY2024: 83.22%Gross margin, FY2025: 59.90%Operating margin, FY2021: -65.50%Operating margin, FY2022: -57.47%Operating margin, FY2023: -21.54%Operating margin, FY2024: 11.47%Operating margin, FY2025: -29.92%Net margin, FY2021: -59.66%Net margin, FY2022: -75.40%Net margin, FY2023: -43.11%Net margin, FY2024: 12.37%Net margin, FY2025: -32.45%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 86.17%. Gross margin FY2022 85.00%. Gross margin FY2023 87.91%. Gross margin FY2024 83.22%. Gross margin FY2025 59.90%. Operating margin FY2021 -65.50%. Operating margin FY2022 -57.47%. Operating margin FY2023 -21.54%. Operating margin FY2024 11.47%. Operating margin FY2025 -29.92%. Net margin FY2021 -59.66%. Net margin FY2022 -75.40%. Net margin FY2023 -43.11%. Net margin FY2024 12.37%. Net margin FY2025 -32.45%.

Income trends

Revenue

2.2B USD+15.58%

Operating income

−657.77M USD−875.85M USD

Net income

−713.41M USD−948.65M USD
Income trends across reported periods2.49B USD1.32B USD160.08M USD−1B USDRevenue, FY2021: 701.89M USDRevenue, FY2022: 933.01M USDRevenue, FY2023: 1.24B USDRevenue, FY2024: 1.9B USDRevenue, FY2025: 2.2B USDOperating income, FY2021: −459.71M USDOperating income, FY2022: −536.2M USDOperating income, FY2023: −267.82M USDOperating income, FY2024: 218.08M USDOperating income, FY2025: −657.77M USDNet income, FY2021: −418.78M USDNet income, FY2022: −703.49M USDNet income, FY2023: −535.98M USDNet income, FY2024: 235.24M USDNet income, FY2025: −713.41M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 701.89M USD. Revenue FY2022 933.01M USD. Revenue FY2023 1.24B USD. Revenue FY2024 1.9B USD. Revenue FY2025 2.2B USD. Operating income FY2021 −459.71M USD. Operating income FY2022 −536.2M USD. Operating income FY2023 −267.82M USD. Operating income FY2024 218.08M USD. Operating income FY2025 −657.77M USD. Net income FY2021 −418.78M USD. Net income FY2022 −703.49M USD. Net income FY2023 −535.98M USD. Net income FY2024 235.24M USD. Net income FY2025 −713.41M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.2B USD1.9B USD1.24B USD933.01M USD701.89M USD
Cost of goods sold881.5M USD319.1M USD150.34M USD139.99M USD97.05M USD
Gross profit1.32B USD1.58B USD1.09B USD793.02M USD604.84M USD
Research and development1.52B USD804.52M USD877.39M USD877.09M USD771.18M USD
Selling, general, and administrative478.94M USD557.87M USD481.87M USD451.42M USD282.66M USD
Operating expenses1.97B USD1.36B USD1.36B USD1.33B USD1.06B USD
Interest income19.57M USD71.77M USD85.97M USD27.72M USD511K USD
Interest expense9.73M USD18.39M USD22.01M USD53.25M USD63.53M USD
Depreciation and amortization44.52M USD37.72M USD44.4M USD41.86M USD38.02M USD
Operating income−657.77M USD218.08M USD−267.82M USD−536.2M USD−459.71M USD
Net income−713.41M USD235.24M USD−535.98M USD−703.49M USD−418.78M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+649.99%
11 comparable reports
Latest EPS result
-0.05
Estimate 0.22 · Miss by 123.01%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.780.78-2.22-5.22Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 1.5, estimate 1.38, surprise +8.70%, Beat. Q2 2025, reported May 6, 2025: actual -4.6, estimate -0.87, surprise -428.74%, Miss. Q3 2025, reported Aug 6, 2025: actual 2.02, estimate 0.832, surprise +142.79%, Beat. Q4 2025, reported Nov 3, 2025: actual -1.8, estimate -0.727, surprise -147.60%, Miss. Q1 2026, reported Feb 25, 2026: actual -3.58, estimate -1.03, surprise -247.57%, Miss. Q2 2026, reported May 6, 2026: actual 3.16, estimate 0.976, surprise +223.77%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.05, estimate 0.217, surprise -123.01%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.156, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates777.58M619.4M461.22M303.03MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 658.41M USD, estimate 631.03M USD, surprise +4.34%, Beat. Q2 2025, reported May 6, 2025: actual 744.86M USD, estimate 687.47M USD, surprise +8.35%, Beat. Q3 2025, reported Aug 6, 2025: actual 611.09M USD, estimate 530.66M USD, surprise +15.16%, Beat. Q4 2025, reported Nov 3, 2025: actual 399.36M USD, estimate 335.76M USD, surprise +18.94%, Beat. Q1 2026, reported Feb 25, 2026: actual 442.93M USD, estimate 369.6M USD, surprise +19.84%, Beat. Q2 2026, reported May 6, 2026: actual 730.8M USD, estimate 474.16M USD, surprise +54.13%, Beat. Q3 2026, reported Aug 5, 2026: actual 401.25M USD, estimate 366.39M USD, surprise +9.51%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 353.81M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.11

33.63% upside
Past 12 months12-month forecastHigh $35.00Average $25.11Low $14.00

Rating distribution

55 ratings
Strong buy00%
Buy3156%
Hold1833%
Sell611%
Strong sell00%

SRPT news

defenseworld.net

Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT

Bank of America Corp DE increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 26.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…

Read source
zacks.com

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Read source
marketbeat.com

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics NASDAQ: SRPT reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating…

Read source
defenseworld.net

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics (NASDAQ: SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating…

Read source
seekingalpha.com

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $2.02 per share a year ago.

Read source

Corporate actions

Corporate action history

Stock split

Effective Jul 12, 2012

1:6

SRPT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SRPT

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
116.64M
Weight
0.10%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
First Trust NYSE Arca Biotechnology Index Fund logoFirst Trust NYSE Arca Biotechnology Index FundFBT
Market value
91.41M
Weight
3.14%
AUM
2.94B USD
Expense ratio
0.55%
Price / 1D
$271.07+1.10%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
89.75M
Weight
0.79%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
51.05M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
47.45M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
34.26M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
19.79M
Weight
0.04%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
18.98M
Weight
0.11%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%

Continue in GoAI

Research SRPT

research.disclaimer